Orforglipron Foundayo

1. What Is Foundayo?

FDA announced on April 1, 2026 that it approved Foundayo, generic name orforglipron, through the Commissioner's National Priority Voucher pilot program. FDA approval documents identify the application as NDA 220934, and labeling describes Foundayo as tablets for oral use.

For recordkeeping, that makes Foundayo different from injectable semaglutide or tirzepatide workflows. It is still a GLP-1-related record, but the practical fields change: tablets, oral schedule, inventory counts, refill context, side-effect notes, metrics, labs, and exports.

The tracking point is not that a pill is simpler in every way. It is simpler in some fields and more important in others. Injection-site rotation may drop away, but dose timing, tablet strength, missed or late records, refill dates, and oral inventory become the center of the record.

That distinction matters when comparing oral GLP-1 tracking with injection tracking. Foundayo records need to answer the product question, the route question, and the recordkeeping question without turning into dosing advice.

2. What Changes When the GLP-1 Is Oral?

Oral GLP-1 records shift the tracking focus entirely. Because Foundayo is approved as an oral tablet (DailyMed, 2026), injection-site rotation, vial reconstitution, and syringe units are no longer needed. Instead, tablet timing, dose strength, missed or late records, inventory count, refill notes, and side-effect entries become the primary metrics.

FDA labeling describes Foundayo as tablets for oral use, which gives the record a different shape from an injectable pen or vial. A user may still want reminders, progress metrics, bloodwork notes, side-effect notes, and exports, but the inventory item is a tablet supply instead of an injectable supply.

What does not belong in a Foundayo-only log? Injection-site rotation, reconstitution math, needle notes, and syringe-unit conversion fields are not the core record unless the user is also tracking an injectable item. The record shape should follow the form instead of forcing every GLP-1 into the same template.

3. How Can Peptide Tracker Store Foundayo Records?

Peptide Tracker supports oral inventory items as well as vials, pens, sprays, topicals, and other forms. For Foundayo, that means a user-entered oral item can sit beside logs, schedules, side-effect notes, bloodwork, metrics, Apple Health imports, progress photos, and exports.

The app does not interpret the FDA label, choose dose strength, or decide whether Foundayo fits a person. It can keep a record readable: what was entered, when it was entered, what inventory item it belonged to, what notes were attached, and what still needs outside review.

That readability matters when a timeline includes more than medication logs. A user may want to compare dates with weight entries, glucose values, blood pressure, sleep notes, lab records, refill timing, cost notes, or side-effect entries. Peptide Tracker can group those records without turning the grouping into a medical conclusion.

For adjacent workflows, see GLP-1 tracking overview, progress tracking, and peptide journaling.

4. Clinical Progress Baselines

Public trial results can give recordkeeping context for weight entries, but they are not personal expectations or dosing guidance. The obesity and weight-management studies below used different designs and populations, so the figures should be read as source context rather than a prediction for any one user.

ATTAIN-1 and ATTAIN-2 used 36 mg capsule dosing in the trials; FDA-approved Foundayo tablet strengths use different numeric tablet doses. This page is about record context, not dose conversion.

5. Foundayo vs Injectable GLP-1 Tracking

Foundayo tracking and injectable GLP-1 tracking share the same core idea: keep user-entered records clear, dated, and exportable. The difference is the surrounding workflow. FDA identifies Foundayo as oral tablets under NDA 220934 (FDA Approval Letter, 2026), while products such as Wegovy and Zepbound are injectable products with pen-based instructions in their labeling.

For an injectable product, a useful record may include shot date, body area, injection-site reaction, pen or vial inventory, and reminder timing. For Foundayo, the most useful record shifts toward tablet supply, oral schedule, late or missed entries, refill timing, and source notes.

It is a mistake to treat "GLP-1 tracker" as one identical workflow. The receptor class may be shared, but the practical record changes when the form changes from injection to tablet.

6. What Should a Foundayo Export Include?

A useful Foundayo export should include the medication name, oral form, date and time records, user-entered strength, notes, inventory context, side-effect records, progress metrics, bloodwork entries, and any questions saved for later review. It should not include app-generated treatment instructions.

PDF is useful for a readable summary. CSV is useful when the user wants spreadsheet analysis or a backup. TXT is useful when a plain timeline matters more than formatting. The point is not one perfect export format; it is preserving structured records in formats that still work outside the app.

A Foundayo export should also make the oral route obvious. That prevents the record from being confused with injectable GLP-1 workflows that include injection sites, pen changes, vial notes, or syringe-unit calculations. The route is not a small detail; it changes the record shape.

7. What Questions Should Foundayo Records Keep Handy?

Foundayo records should keep practical questions close to the timeline: when was the tablet logged, was the record late, which inventory item was used, were side effects noted, did metrics change, and is there a refill or cost note to review. Those questions are recordkeeping questions.

They are not dosing instructions. The app can preserve questions for a clinician, pharmacist, or other qualified professional, but it should not answer them as medical guidance.

8. Sources